Phio Pharmaceuticals Corp - Asset Resilience Ratio
Phio Pharmaceuticals Corp (PHIO) has an Asset Resilience Ratio of 1.31% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Phio Pharmaceuticals Corp's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2017)
This chart shows how Phio Pharmaceuticals Corp's Asset Resilience Ratio has changed over time. See PHIO equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Phio Pharmaceuticals Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Phio Pharmaceuticals Corp (PHIO) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.00K | 1.31% |
| Total Liquid Assets | $50.00K | 1.31% |
Asset Resilience Insights
- Limited Liquidity: Phio Pharmaceuticals Corp maintains only 1.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Phio Pharmaceuticals Corp Industry Peers by Asset Resilience Ratio
Compare Phio Pharmaceuticals Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Phio Pharmaceuticals Corp (2012–2017)
The table below shows the annual Asset Resilience Ratio data for Phio Pharmaceuticals Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 1.22% | $50.00K | $4.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $13.40 Million | -- |
| 2015-12-31 | 49.29% | $5.50 Million | $11.16 Million | +48.74pp |
| 2014-12-31 | 0.54% | $50.00K | $9.19 Million | -19.54pp |
| 2013-12-31 | 20.08% | $3.00 Million | $14.94 Million | +19.14pp |
| 2012-12-31 | 0.95% | $53.00K | $5.59 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more